A Randomized Double-Blind, Placebo-controlled Dose Escalating Study of the Pharmacokinetics, Safety and Tolerability of Testosterone Undecanoate (ABT-SLV361) in Hypogonadal Males.
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2011
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Hypogonadism
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Abbott Laboratories
- 02 Nov 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 02 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Aug 2011 Planned end date changed from Jul 2011 to Sep 2011 as reported by ClinicalTrials.gov.